Aura Biosciences, Inc.

Aura Biosciences, Inc. no longer discloses a going-concern conclusion

Substantial doubt raised, alleviated by management's plans → No going-concern disclosure

Source filing ↗ Prior filing ↗

Aura Biosciences, Inc. said management's plans alleviate substantial doubt about going concern

No going-concern disclosure → Substantial doubt raised, alleviated by management's plans

Other than the termination of the prospectus, the Sales Agreement remains in full force and effect. As disclosed in the Company’s audited consolidated financial statements as of and for the year ended December 31, 2025, events and conditions existed which raised substantial doubt about the Company’s ability to continue as a going concern, primarily due to recurring operating losses, negative cash flows from operations and liquidity constraints. Subsequent to year end, the Company completed the 2026 Follow-On Offering, raising approximately $241.8 million in net proceeds after completion of…

Source filing ↗ Prior filing ↗

Aura Biosciences, Inc. disclosed substantial doubt about its ability to continue as a going concern

No going-concern disclosure → Substantial doubt about ability to continue as a going concern

Our auditors have issued a “going concern” audit opinion. Management has determined and our independent auditors have indicated in their report on our December 31, 2025 financial statements that there is substantial doubt about our ability to continue as a going concern. A “going concern” paragraph in an audit opinion means that there is substantial doubt that we can continue as an ongoing business for the twelve months from the date the consolidated financial statements are issued. If we are unable to continue as an ongoing business, we might have to liquidate our assets and the values we…

Source filing ↗ Prior filing ↗